HOYA Corporation (HOCPY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HOYA Corporation (HOCPY) trades at $158.60 with AI Score 56/100 (Grade B). HOYA Corporation is a global med-tech company providing life care and information technology products. Market cap: $53.05B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026HOCPY stock analysis for 2026: Analysts have set a consensus price target of $201.94 for HOYA Corporation, suggesting 27.3% upside from the current price of $158.60. The AI MoonshotScore is 56/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
HOCPY: 3/7 perspectives are bullish. Dominant signal: Ken Griffin bearish.
How is this calculated? →HOYA Corporation (HOCPY) Healthcare & Pipeline Overview
HOYA Corporation, a Japanese med-tech leader, supplies life care products like eyeglass lenses and medical endoscopes, alongside IT products such as semiconductor components. With a $53.05B market cap and a 27.3% profit margin, HOYA leverages its diversified portfolio and global reach to maintain a competitive edge in the healthcare and technology sectors.
What Is the Investment Thesis for HOCPY?
HOYA Corporation presents a compelling investment case based on its diversified revenue streams and strong profitability. With a market capitalization of $53.05B and a profit margin of 27.3%, HOYA demonstrates financial stability. Key value drivers include the growing demand for medical endoscopes and advanced optical components. Growth catalysts include expansion in emerging markets and continued innovation in its product lines. Potential risks include currency fluctuations and increased competition in the medical device market. The company's consistent dividend yield of 0.87% further enhances its appeal to income-seeking investors.
Based on FMP financials and quantitative analysis
HOCPY Key Highlights
- Market Cap of $53.05B reflects HOYA's significant presence in the med-tech and IT sectors.
- P/E ratio of 37.7 indicates investor confidence in HOYA's earnings potential.
- Profit Margin of 27.3% showcases HOYA's efficient operations and strong pricing power.
- Gross Margin of 79.8% highlights the high value-added nature of HOYA's products and services.
- Beta of 0.60 suggests lower volatility compared to the overall market, appealing to risk-averse investors.
Who Are HOCPY's Competitors?
HOCPY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARGNF argenx SE | $803.19 | -10.76% | $49.70B | 49 |
| CMXHF CSL Limited | $86.80 | +4.35% | $41.57B | 48 |
| LZAGF Lonza Group AG | $727.70 | +2.85% | $50.83B | 42 |
| LZAGY Lonza Group AG | $72.25 | +2.59% | $51.41B | 44 |
| MKGAF Merck KGaA | $170.15 | +0.09% | $73.98B | 46 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| STXS Stereotaxis, Inc. | $1.88 | +5.03% | $183.74M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HOCPY's Key Strengths?
- Diversified product portfolio across healthcare and technology.
- Strong global presence and distribution network.
- High profit margin and gross margin.
- Technological expertise in optics and materials science.
What Are HOCPY's Weaknesses?
- Exposure to currency fluctuations.
- Dependence on semiconductor industry cycles.
- Potential for increased competition in medical devices.
- Limited brand recognition compared to some competitors.
What Could Drive HOCPY Stock Higher?
- Increasing demand for medical endoscopes due to minimally invasive surgery trends.
- Growth in the intraocular lens market driven by the aging population.
- Potential expansion into new geographic markets in Asia and Latin America by 2027.
- Continued innovation in semiconductor mask blanks for advanced chip manufacturing.
- Development and expansion of cloud-based healthcare solutions.
What Are the Key Risks for HOCPY?
- Rich valuation — a P/E of 37.7 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Currency fluctuations affecting the value of ADR shares.
- Economic downturns impacting healthcare spending and demand for elective procedures.
- Increased competition in the medical device and semiconductor industries.
- Regulatory changes in healthcare and technology sectors.
- Dependence on the semiconductor industry cycle.
What Are the Growth Opportunities for HOCPY?
- Expansion in the Medical Endoscopy Market: The global medical endoscopy market is projected to reach $45 billion by 2028, driven by increasing demand for minimally invasive surgical procedures. HOYA's advanced endoscope technology and established distribution network position it to capture a significant share of this growing market. Investment in R&D to develop next-generation endoscopes with enhanced imaging capabilities will further solidify its competitive advantage.
- Growth in Intraocular Lenses (IOLs): The global IOL market is expected to reach $5 billion by 2027, fueled by the aging population and rising prevalence of cataracts. HOYA's innovative IOL designs and strong relationships with ophthalmic surgeons provide a solid foundation for growth in this sector. Strategic partnerships with eye clinics and hospitals can further expand its market reach.
- Penetration of Emerging Markets: Emerging markets, particularly in Asia and Latin America, offer significant growth opportunities for HOYA. Increasing healthcare spending and rising awareness of advanced medical technologies are driving demand for HOYA's products. Establishing local manufacturing facilities and distribution networks in these regions can enhance its competitiveness and market penetration.
- Advancements in Semiconductor Mask Blanks: The semiconductor industry is experiencing rapid growth, driven by demand for advanced chips in various applications. HOYA's mask blanks are essential components in semiconductor manufacturing. Investing in R&D to develop mask blanks for next-generation chips and expanding production capacity can capitalize on this growth opportunity. The global semiconductor market is projected to reach $1 trillion by 2030.
- Development of Cloud-Based Healthcare Solutions: The healthcare industry is increasingly adopting cloud-based solutions for data management and patient care. HOYA's ReadSpeaker and Kinnosuke cloud services can be expanded to offer comprehensive healthcare solutions. Developing partnerships with healthcare providers and integrating AI-powered analytics can enhance the value proposition of these services.
What Opportunities Does HOCPY Have?
- Expansion in emerging markets.
- Growth in medical endoscopy and intraocular lens markets.
- Development of cloud-based healthcare solutions.
- Advancements in semiconductor mask blanks.
What Threats Does HOCPY Face?
- Economic downturns affecting healthcare spending.
- Technological disruptions in medical devices and semiconductor manufacturing.
- Regulatory changes in healthcare and technology sectors.
- Increased competition from established and emerging players.
What Are HOCPY's Competitive Advantages?
- Technological expertise in optics and materials science.
- Diversified product portfolio across healthcare and technology sectors.
- Established global distribution network.
- Strong brand reputation for quality and innovation.
What Does HOCPY Do?
Founded in 1941 in Tokyo, Japan, HOYA Corporation initially focused on manufacturing optical lenses. Over the decades, HOYA strategically expanded its portfolio to become a diversified med-tech company. Today, HOYA operates globally, offering a wide array of products and services across two primary segments: Life Care and Information Technology. The Life Care segment includes eyeglass lenses, contact lenses (sold through its Eyecity retail chain), medical endoscopes, intraocular lenses, and surgical instruments. The Information Technology segment produces mask blanks and photomasks for semiconductor manufacturing, glass disks for hard disk drives, and imaging-related products. HOYA's evolution reflects its commitment to innovation and adaptation to changing market demands, solidifying its position as a key player in both the healthcare and technology industries.
What Products and Services Does HOCPY Offer?
- Develop and manufacture eyeglass and contact lenses for vision correction.
- Produce medical endoscopes for diagnostic and surgical procedures.
- Create intraocular lenses for cataract surgery.
- Manufacture laparoscopic surgical instruments.
- Provide automatic endoscope cleaning equipment.
- Supply mask blanks and photomasks for semiconductor chip manufacturing.
- Produce glass disks for hard disk drives.
- Offer speech synthesis software (ReadSpeaker) and cloud services.
How Does HOCPY Make Money?
- Manufacturing and sales of life care products (eyeglass lenses, contact lenses, medical devices).
- Manufacturing and sales of information technology products (semiconductor components, glass disks).
- Retail sales of contact lenses through its Eyecity chain.
- Software and cloud service subscriptions (ReadSpeaker, Kinnosuke, Yonosuke).
What Industry Does HOCPY Operate In?
HOYA Corporation operates within the rapidly evolving medical instruments and supplies industry, driven by technological advancements and increasing healthcare expenditure. The global medical device market is projected to reach $600 billion by 2026. HOYA's competitive landscape includes companies like ARGNF (Alcon), CMXHF (Carl Zeiss Meditec), LZAGF (EssilorLuxottica), LZAGY (EssilorLuxottica), and MKGAF (Nikon), each vying for market share through innovation and strategic partnerships. HOYA's diversified portfolio and global presence position it favorably to capitalize on these trends.
Who Are HOCPY's Key Customers?
- Eye care professionals (optometrists, ophthalmologists).
- Hospitals and surgical centers.
- Semiconductor manufacturers.
- Data storage companies.
- Businesses and organizations using speech synthesis software and cloud services.
How HOYA Corporation Is Valued
HOYA Corporation carries a market capitalization of $53.05B, placing it in the large-cap category. Relative to its peer group, HOCPY's quantitative score of 56/100 is above the peer average of 46/100.
Company Profile
HOYA Corporation operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Eiichiro Ikeda. HOCPY has traded publicly since 2007.
ROE 25%Key Financial Metrics
Return on equity for HOYA Corporation stands at 25.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 19.5%, showing how much profit it generates from its asset base. HOCPY trades at a trailing price-to-earnings ratio of 37.72, above the Healthcare sector average of ~23x. Its free cash flow yield is 2.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.81 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 5/9Financial Health
HOYA Corporation's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 22.51 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project HOYA Corporation revenue of about $956.00B for fiscal 2026, with EPS near $744.72. The estimate reflects 8 contributing analysts.
HOCPY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in HOYA's growth trajectory, indicating management believes in the company's future.
- Community sentiment has shifted positively, with discussions highlighting HOYA's advancements in optical technology and healthcare solutions.
- Analysts have noted increased demand for HOYA's products, especially in the medical sector, bolstering the company's reputation.
- Market perception has improved as HOYA continues to innovate, positioning itself well against competitors in the optical and healthcare fields.
Bear Case
- Concerns over global supply chain disruptions could impact HOYA's production capabilities and delivery timelines.
- Recent bearish sentiment in online forums suggests some investors are wary of potential market volatility affecting HOYA's stock performance.
- Insider selling activity has raised eyebrows, leading to speculation about potential challenges the company may face in the near term.
- The competitive landscape is intensifying, with rivals launching similar products, which could pressure HOYA's market share and margins.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HOCPY Latest News
-
DKILY vs. HOCPY: Which Stock Is the Better Value Option?
zacks.com · May 14, 2026
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Wednesday
· Dec 4, 2019
HOCPY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HOCPY.
Price Targets
Consensus target: $201.94
HOCPY MoonshotScore
What does this score mean?
The MoonshotScore rates HOCPY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Eiichiro Ikeda
CEO
Eiichiro Ikeda serves as the CEO of HOYA Corporation, leading a global workforce of over 35,000 employees. His career spans several decades in the technology and healthcare sectors. Prior to becoming CEO, Ikeda held various leadership positions within HOYA, overseeing strategic planning, product development, and global operations. He holds advanced degrees in engineering and business administration, providing a strong foundation for his leadership role.
Track Record: Under Eiichiro Ikeda's leadership, HOYA Corporation has achieved significant milestones, including expansion into new markets and the successful launch of innovative products. He has focused on driving operational efficiency and fostering a culture of innovation within the company. His strategic decisions have contributed to HOYA's consistent financial performance and growth in key business segments.
HOYA Corporation ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. HOCPY is a Level 1 ADR, meaning it trades over-the-counter (OTC) without needing to meet the strict listing requirements of exchanges like the NYSE or NASDAQ. This allows U.S. investors to invest in HOYA Corporation more easily.
- Home Market Ticker: Tokyo Stock Exchange, Japan
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: HOCP
HOCPY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of transparency and regulatory oversight compared to listed companies. Investors should exercise caution and conduct thorough due diligence before investing.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in HOCPY.
- Lower liquidity can lead to price volatility and difficulty in trading.
- OTC Other tier status indicates a higher risk profile compared to listed companies.
- Potential for fraud or manipulation in the OTC market.
- Lack of regulatory oversight may expose investors to greater risks.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's management team and track record.
- Research the company's industry and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues involving the company.
- HOYA Corporation is a well-established company with a long operating history.
- The company has a significant market capitalization, suggesting a substantial business.
- HOYA Corporation is listed on the Tokyo Stock Exchange, indicating some level of regulatory compliance.
- The company has a diversified product portfolio and global presence.
- HOYA Corporation has a positive profit margin, suggesting financial stability.
What Investors Ask About HOYA Corporation (HOCPY) — Healthcare
What does HOYA Corporation do?
HOYA Corporation is a global med-tech company that operates in two primary segments: Life Care and Information Technology. In Life Care, HOYA develops and manufactures eyeglass lenses, contact lenses (sold through its Eyecity retail chain), medical endoscopes, intraocular lenses, and surgical instruments. In Information Technology, HOYA produces mask blanks and photomasks for semiconductor manufacturing, glass disks for hard disk drives, and imaging-related products. HOYA also offers speech synthesis software and cloud services.
What are the main risks for HOCPY?
HOYA Corporation faces several risks, including currency fluctuations that can impact the value of its ADR shares. Economic downturns can affect healthcare spending and demand for elective procedures. Increased competition in the medical device and semiconductor industries poses a threat to market share. Regulatory changes in healthcare and technology sectors can impact operations and profitability. Additionally, HOYA is dependent on the cyclical nature of the semiconductor industry.
What revenue streams does HOYA Corporation have in healthcare?
HOYA Corporation's healthcare revenue streams are diversified across several key product lines. A significant portion comes from eyeglass and contact lenses, sold both directly and through its Eyecity retail chain. Medical endoscopes and related surgical instruments contribute substantially, driven by the increasing adoption of minimally invasive procedures. Intraocular lenses (IOLs) for cataract surgery represent another important revenue stream, benefiting from the aging global population. These streams are geographically diverse, with sales across North America, Europe, Asia, and other regions.
How does HOYA Corporation manage patent expiration risks?
As a med-tech company, HOYA Corporation faces patent expiration risks on its medical devices and technologies. To mitigate this, HOYA invests heavily in research and development to create new and innovative products with patent protection. The company also employs lifecycle management strategies, such as developing next-generation versions of existing products and securing patents on improvements or modifications. Furthermore, HOYA actively monitors the competitive landscape and prepares for potential biosimilar or generic competition by diversifying its product portfolio and focusing on high-value, differentiated offerings.
What are the key factors to evaluate for HOCPY?
HOYA Corporation (HOCPY) holds an AI score of 56/100 (moderate). P/E: 37.7x vs the S&P 500's ~20-25x. Analysts target $201.94 (+27%). Not financial advice.
How frequently does HOCPY data refresh on this page?
HOCPY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HOCPY's recent stock price performance?
HOYA Corporation (HOCPY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio across healthcare and technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HOCPY overvalued or undervalued right now?
HOYA Corporation (HOCPY) trades at 37.7x earnings. Analysts target $201.94 (+27%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for HOCPY, limiting comprehensive insights.
- OTC market data may have limited reliability.